TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11152019
Drug: Delavirdine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine as a first‐line therapy with 2 NRTIs
Study: 8967600
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nitrous oxide and enflurane
Study: 2426934
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (5000 IU bolus followed by 830 IU/hr for 2 hours)
Study: 2426934
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (5000 IU bolus)
Study: 17227525
Drug: Neostigmine 0.5
Normalized name: neostigmine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.5 mg IV
Study: 12374900
Drug: Imidapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5 to 10 mg per day)
Study: 12374900
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 to 50 mg twice per day)
Study: 9825268
Drug: Furosemide infusion
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide infusion (2 x 40 mg)
Study: 9825268
Drug: Furosemide bolus
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide bolus injection (2 x 40 mg)
Study: 9825268
Drug: Furosemide infusion
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide infusion
Study: 9825268
Drug: Furosemide bolus
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide bolus injection
Study: 8120709
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (8 gm daily, containing 3.2 gm eicosapentaenoic acid and 2.2 gm docosahexaenoic acid)
Study: 990700
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet as preoperative bowel preparation
Study: 990700
Drug: Routine bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine bowel preparation
Study: 24824660
Drug: D-Cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-Cycloserine (DCS) administered at a dosage of 50 mg either once weekly or daily for 8 weeks.
Study: 24824660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified in detail, but implied to be a placebo or no treatment).
Study: 18678823
Drug: DHEA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 100 mg/d
Study: 18678823
Drug: DHEA 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 400 mg/d
Study: 10084491
Drug: Positional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positional treatment
Study: 525733
Drug: Domperidone given
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone given prophylactically with morphine
Study: 1915517
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose salicylate (100 mg/kg per day)
Study: 1915517
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose salicylate (30 mg/kg per day)
Study: 29027116
Drug: Intracoronary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary and intravenous melatonin (total 50 mg)
Study: 23928707
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration group (ropivacaine 0.2% infusion)
Study: 23928707
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration group (ropivacaine 0.1% infusion)
Study: 23928707
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion group (saline 0.9% infusion)
Study: 21305734
Drug: PreOp group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PreOp group (carbohydrate drink 200 mL two hours before surgery)
Study: 12037148
Drug: hOKT3gamma1(Ala‐Ala) monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment for 14 days
Study: 12037148
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibody treatment)
Study: 12037148
Drug: hOKT3gamma1(Ala‐Ala) monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hOKT3gamma1(Ala‐Ala) monoclonal antibody treatment
Study: 26857829
Drug: Multicomponent sun
Normalized name: CLOZAPINE (SUN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent sun protection program (read-along book, swim shirt, weekly text-message reminders)
Study: 24534682
Drug: Multi-media tablet
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-media tablet device delivering graphic and verbal information
Study: 16083521
Drug: Trazodone prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone prolonged release 150-450 mg/day (n = 55)
Study: 16083521
Drug: Paroxetine 20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20-40 mg/day (n = 53)
Study: 12404164
Drug: Repeated treatment
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated treatment with praziquantel
Study: 12404164
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (children who did not receive chemotherapy)
Study: 10594405
Drug: L-Arginine (L-Arg)
Normalized name: L-Arg
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (L-Arg)
Study: 10594405
Drug: L-NMMA +
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA + L-Arg
Study: 8677930
Drug: 125-mg 13C
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 125-mg 13C urea breath test at 30 min
Study: 8677930
Drug: 250-mg 13C
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250-mg 13C urea breath test at 40 min
Study: 8677930
Drug: 125-mg 13C
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 125-mg 13C urea breath test
Study: 1961376
Drug: Azathioprine (Germed)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (Germed) 50 or 75 mg daily depending on body weight, treatment stopped after two months for one month
Study: 1961376
Drug: Prednisone (Encorton,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (Encorton, Polfa) 5 or 10 mg daily
Study: 26971745
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shockwave therapy (rESWT) - 0.340 mJ/mm2, 2000 shots
Study: 19089890
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg twice per day + Vaginal conjugated equine estrogen 0.625 mg twice a week
Study: 19089890
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg twice per day
Study: 11430419
Drug: Standard-dose lenograstim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose lenograstim (263 microg/day)
Study: 11430419
Drug: Low-dose lenograstim
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lenograstim (131.5 microg/day)
Study: 2635871
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg suppositories twice daily)
Study: 2635871
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo suppositories)
Study: 415870
Drug: 4-methylpyrazole (4-MP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-methylpyrazole (4-MP, 7 mg/kg body wt i.v.)
Study: 415870
Drug: Ethanol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.6 g/kg body wt)
Study: 26164096
Drug: Treatment including
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment including doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg + doxorubicin 50 mg/m² every 6 weeks)
Study: 26164096
Drug: Treatment excluding
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment excluding doxorubicin (vincristine 1.5 mg/m² + actinomycin D 45 μg/kg)
Study: 24166522
Drug: G‐CSF 1‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 1‐6 cycles
Study: 24166522
Drug: G‐CSF 1‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 1‐2 cycles
Study: 24166522
Drug: G‐CSF 1‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 1‐6 cycles vs G‐CSF 1‐2 cycles
Study: 19476724
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group (standard treatment with nurse feedback)
Study: 17708161
Drug: HyperHaes solution
Normalized name: Hyperhep B Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperHaes solution (250ml 7.2% NaCl/6% HES solution)
Study: 17708161
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate (500 ml Ringer's acetate solution)
Study: 11521723
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (Herceptin)
Study: 3285731
Drug: Diazepam po
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam po (0.1 mg.kg‐1)
Study: 25111236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of an angiotensin I-converting enzyme inhibitor and angiotensin II-receptor blocker
Study: 25111236
Drug: Angiotensin I-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin I-converting enzyme inhibitor alone
Study: 21954530
Drug: T-piece (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-piece (4 L/min)
Study: 19700946
Drug: Brief psychosocial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychosocial therapy (BPST) for 4 weeks
Study: 15324466
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg) alone
Study: 15324466
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg) plus Ivermectin (200 microg/kg)
Study: 15324466
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg) plus Albendazole (400 mg)
Study: 11153551
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2 microg/kg) 5 min before MH placement
Study: 11153551
Drug: Local lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local lidocaine infiltration (3 ml 1% plain lidocaine) at each pin site 1 min before MH placement
Study: 11153551
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl + local lidocaine infiltration
Study: 9342546
Drug: 37/40 kD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37/40 kD antibodies in Type 1a diabetic patients
Study: 9342546
Drug: 37/40 kD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37/40 kD antibodies in Type 1b diabetic patients
Study: 9342546
Drug: GAD antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibodies and/or 37/40 kD antibodies
Study: 9342546
Drug: GAD antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibodies in schoolchildren
Study: 9342546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ICA with at least two other markers in relatives
Study: 9342546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multiple antibodies in ICA-positive non-diabetic subjects
Study: 1547194
Drug: niacin/colestipol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin/colestipol plus diet therapy
Study: 22607563
Drug: Oral mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mercaptopurine (0.5 mg/kg per day)
Study: 21135366
Drug: ICD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD with appropriate therapy
Study: 21135366
Drug: ICD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD with no appropriate therapy
Study: 21135366
Drug: ICD shock
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICD shock therapy
Study: 21135366
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy (Control, n=342)
Study: 17624213
Drug: Ginseng supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng supplementation (3 grams of 100% ginseng orally daily for 8 weeks)
Study: 17624213
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose powder, same dosage and duration as ginseng)
Study: 15903359
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (6 g of creatine monohydrate per day)
Study: 9523367
Drug: Fenoterol inhalation
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol inhalation
Study: 11050693
Drug: EPI-10 (glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-10 (glyceryl trinitrate transdermal patch)
Study: 11050693
Drug: ND-10 (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-10 (reference patch)
Study: 9282973
Drug: Age effect
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age effect on marker excretion
Study: 3576660
Drug: Chewable tablet
Normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet formulation
Study: 27006510
Drug: Standard glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycemic treatment (Control)
Study: 24736279
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of telmisartan
Study: 22344551
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg exenatide single dose
Study: 22344551
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg exenatide single dose
Study: 22344551
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg exenatide multiple doses
Study: 22344551
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg exenatide multiple doses
Study: 22344551
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events after 5 μg exenatide
Study: 22344551
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events after 10 μg exenatide
Study: 10940515
Drug: Human natural
Normalized name: Human natural killer-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human natural leucocytic interferon (HNLI) applied locally at 2x10(6) U daily in pessaries for 21 days before surgery
Study: 10940515
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with HNLI)
Study: 9263140
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (MTX) plus prednisone > or = 5 mg/day
Study: 9263140
Drug: Prednisone >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone > or = 5 mg/day without MTX
Study: 9263140
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate (MTX)
Study: 3545273
Drug: (‐)‐adrenaline (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: (‐)‐adrenaline (0.06 microgram kg‐1 min‐1 for 90 min) + vehicle control (+)‐glucose infusion (60 min)
Study: 3545273
Drug: salbutamol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol (120 ng kg‐1 min‐1 for 30 min) + vehicle control (+)‐glucose infusion (90 min)
Study: 3545273
Drug: vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle control (+)‐glucose infusion
Study: 24183837
Drug: eGFR 20-44
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR 20-44 mL/min/1.73m(2)
Study: 24183837
Drug: eGFR >
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR > 60 mL/min/1.73m(2)
Study: 24183837
Drug: eGFR <
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR < 60 mL/min/1.73m(2)
Study: 22526314
Drug: Polymorph form
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorph form I of ST-246, 400 mg oral dose
Study: 22526314
Drug: Polymorph form
Normalized name: Angelica polymorpha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorph form V of ST-246, 400 mg oral dose
Study: 29464110
Drug: Study drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drugs
Study: 17928878
Drug: Irbesartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ combination therapy (300 mg/25 mg)
Study: 17928878
Drug: Irbesartan monotherapy
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan monotherapy (300 mg)
Study: 17928878
Drug: HCTZ monotherapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ monotherapy (25 mg)
Study: 11707864
Drug: Bexarotene gel
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene gel applied to target lesions
Study: 11707864
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral bexarotene (300 mg/m²)
Study: 11707864
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral bexarotene (6.5 mg/m²)
Study: 11707864
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral bexarotene (300 mg/m²) for erythrodermic CTCL
Study: 11707864
Drug: Atorvastatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (60 mg/day)
Study: 8806288
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (comparator)
Study: 1321006
Drug: Six-drug alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-drug alternating combination treatment
Study: 1321006
Drug: Three-drug 'standard'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug 'standard' combination treatment
Study: 30902791
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D fortified snack bars (2000 mg Ca and 1000 IU vitamin D per day)
Study: 29803270
Drug: ASA24 (Automated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA24 (Automated Self-Administered 24-Hour Dietary Assessment Tool)
Study: 29803270
Drug: AMPM (Interview-Administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPM (Interview-Administered Automated Multiple Pass Method)
Study: 10992842
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (75‐150 micrograms kg‐1 min‐1)
Study: 8854471
Drug: Pulsed therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed therapy with oral dexamethasone, 40 mg/day on 4 consecutive days each month for 6 months
Study: 8854471
Drug: Dexamethasone tablets
Normalized name: Dexamethasone Tablets
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets
Study: 6515368
Drug: pirbuterol 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirbuterol 0.4 mg
Study: 31590640
Drug: Active program
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active program of knowledge transfer about WHO recommendations for preeclampsia, including antenatal corticosteroids, antihypertensive therapy, and magnesium sulphate for seizure prophylaxis.
Study: 28731266
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1,000 mg/day
Study: 23921600
Drug: Close monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Close monitoring of cerebral rStO2 and a treatment guideline to correct deviations in rStO2
Study: 23921600
Drug: Treatment guideline
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment guideline
Study: 10397375
Drug: Sparfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400 mg loading dose followed by 200 mg once daily for up to 10 days)
Study: 6419519
Drug: Piribedil 40
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil 40 mg
Study: 6419519
Drug: Piribedil 60
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil 60 mg
Study: 6419519
Drug: Piribedil 100
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil 100 mg